Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split

Kinarus Therapeutics Holding AG / Key word(s): Annual Results/Capital Increase Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split 17-Apr-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR

• Publication of audited Consolidated & Statutory FY2023 Financial Statements of Kinarus Therapeutics Holding AG
• Announcement of the postponement of the publication of the Annual Report 2023
• Announcement of details and timeline of the contemplated Reverse Share Split
• Announcement of final timeline for the closing of the previously announced Business Combination of Kinarus Therapeutics Holding AG with Curatis AG
• Announcement of Date for AGM for the financial year 2023 and overall Financial Calendar

Basel, Switzerland, 17 April 2024: Kinarus Therapeutics Holding AG (KNRS.SW) (“Kinarus Holding”, “KNRS.SW” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company today published its audited consolidated FY2023 financial statements (the “FY2023 Consolidated Financial Statements”) and its audited FY2023 statutory financial statements (the “FY2023 Statutory Financial Statements”), together the audited “FY2023 Financial Statements”). Both, Kinarus Holding and its 100% subsidiary, Kinarus AG in Liquidation had filed for bankruptcy in October 2023, but on 5 February 2024, bankruptcy of Kinarus Holding was revoked by the competent courts of Basel-Stadt in the context of the previously announced envisaged Business Combination of Kinarus Holding and Curatis AG, a Basel-Landschaft incorporated specialty medicine distribution and drug development company (“Curatis”). Kinarus AG in Liquidation remains in liquidation. The FY2023 Financial Statements therefore do not provide a comprehensive and transparent picture on the effective financial situation of the Kinarus entities that are to be combined with Curatis in the contemplated Business Combination.